Fundraising Fox
/People
Sign in

Glenn Pierce

Investor

Co-Chair, Investment Committee at Pathway to Cures · Director at Voyager Therapeutics, Inc.

Boston, Massachusetts, United States

Find your path to Glenn

448 people in our graph can introduce you to Glenn.

Each arrow is one introduction. Sign up to fill in the first one.

Ask Steve Paul to introduce you to Glenn

You →Steve · together at Voyager Therapeutics, Inc. (2021–2022) →Glenn

Ask Jamie Chen to introduce you to Glenn

You →Jamie · 5 people · together at Biogen →Glenn

Ask Sam Okafor to introduce you to Glenn

You →Sam · 6 people · together at Third Rock Ventures →Glenn

Sign up to find every way you can get introduced to Glenn

  • Your email: the people you already email who know Glenn
  • 2nd- and 3rd-degree connections: people you know who worked, studied or invested with Glenn
  • Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

Sign up with GoogleAlready have an account? Log in

About

Pierce is an independent consultant and entrepreneur-in-residence at Third Rock Ventures, serving on WFH and NBDF advisory bodies and as a director of Voyager Therapeutics and Global Blood Therapeutics. He retired from Biogen in 2014 as SVP of Hematology, Cell and Gene Therapies.

Director at Voyager Therapeutics, Inc.

Intro paths

→

In turn, Glenn can intro founders to Voyager Therapeutics, Inc.'s investors below.

Voyager Therapeutics, Inc.'s investors · 4

ARCH Venture PartnersChicago · $50K – $250M checks · since 2024Fidelity InvestmentsBostonThird Rock VenturesBoston · $100K – $5M checks · since 2015Wellington ManagementBoston · $5M – $50M checks

Experience

  1. Typewriter, Frontera, Be Bio (to 2026), Metagenomi (to 2026), hC Bio (to 2025), Decibel (to 2023)Scientific Advisory Boardcurrent2020 — presentBoston, San Francisco
  2. Global Blood Therap (2016-22), Voyager Therapeutics (2017-), World Federation of Hemophilia 2015-26Directorcurrent2016 — present
  3. Self EmployedVolunteer, Consultant, Advisorcurrent2015 — present
  4. World Federation of Hemophilia / Fédération mondiale de l'hémophilieVice President, Medical2018 — 2026Greater Montreal Metropolitan Area
  5. Third Rock VenturesEntrepreneur In Residence2016 — 2025San Francisco Bay Area
  6. Voyager Therapeutics, Inc.Interim CSO2021 — 2022Cambridge, Massachusetts, United States
  7. Ambys MedicinesInterim CMO2018 — 2022San Francisco Bay Area
  8. Hiatus-2014 — 2016
  9. BiogenSVP, Hematology, Cell and Gene Therapies2014
  10. BiogenSVP, Global Medical Affairs and Chief Medical Officer, Hemophilia Therapeutic Area2012 — 2014
  11. BiogenSVP and CMO Hemophilia Business2009 — 2012
  12. Bayer HealthCareScientific Head, US Research Center/VP Applied Research2005 — 2009
  13. AvigenVice President Research/Development2002 — 2005
  14. Selective GeneticsVice President, Therapeutic Product Development1994 — 2002
  15. AmgenAssoc Med Director1988 — 1994

Skills & more

Clinical Development99Immunology66Pharmacology38Hematology43Polymers2Partnerships4Biotechnology68Lifesciences7Pharmaceutical Industry39Technology Transfer17Oncology13Drug Discovery22
+8 moreClinical TrialsLipidTissueBiopharmaceuticalsDrug DevelopmentFDACommercializationMolecular Biology

From Glenn's professional profile.

Colleagues at Pathway to Cures

Amy L. Dunn
Chair, Medical and Scientific Advisory Council (MASAC) for NBDF at Pathway to Cures
Beth Whitehouse
NBDF Senior Vice President for Advancement at Pathway to Cures
Brian Andrew
Investment Committee Chair at Pathway to Cures
Christine Brennan
Investment Committee Member at Pathway to Cures
Geeta Vemuri
Managing Partner, Founder at Agent Capital
Gilbert C. White
P2C Board Vice Chair & Secretary at Pathway to Cures
Gilbert C. White, II
P2C Board Vice Chair & Secretary at Pathway to Cures
Haiyan Jiang
Scientific Advisory Group Member at Pathway to Cures

Frequently asked questions

Who is Glenn Pierce?
Pierce is an independent consultant and entrepreneur-in-residence at Third Rock Ventures, serving on WFH and NBDF advisory bodies and as a director of Voyager Therapeutics and Global Blood Therapeutics. He retired from Biogen in 2014 as SVP of Hematology, Cell and Gene Therapies.
Where does Glenn Pierce work?
Glenn Pierce is Co-Chair, Investment Committee at Pathway to Cures.
Where did Glenn Pierce go to school?
Glenn Pierce studied at Washington University School of Medicine in St. Louis (Lab Medicine Residency and Hematology Fellowship/Post-doc); Case Western Reserve University School of Medicine (Internship, Internal Medicine); Case Western Reserve University School of Medicine (MD, PhD).

Same school

Shared employers